Chemotherapy is a mainstay of treatment for solid tumors. However, little is known about how therapy-induced immune cell infiltration may affect therapy response. We found substantial CD45+ immune cell density adjacent to E-selectin expressing inflamed vessels in doxorubicin (DOX)-treated residual human breast tumors. While CD45 level was significantly elevated in DOX-treated wildtype mice, it remained unchanged in DOX-treated tumors from E-selectin null mice. Similarly, intravenous administration of anti-E-selectin aptamer (ESTA) resulted in a significant reduction in CD45+ immune cell density in DOX-treated residual tumors, which coincided with a delay in tumor growth and lung metastasis in MMTV-pyMT mice. Additionally, both tumor infiltrating T-lymphocytes and tumor associated-macrophages were skewed towards TH2 in DOX-treated residual breast tumors; however, ESTA suppressed these changes. This study suggests that DOX treatment instigates de novo intratumoral infiltration of immune cells through E-selectin, and functional blockade of E-selectin may reduce residual tumor burden as well as metastasis through suppression of TH2 shift.
Recommended CitationMorita, Yoshihiro; Leslie, Macall; Kameyama, Hiroyasu; Lokesh, Ganesh L R; Ichimura, Norihisa; Davis, Rachel; Hills, Natalie; Hasan, Nafis; Zhang, Roy; Kondo, Yuji; Gorenstein, David G; Volk, David E; Chervoneva, Inna; Rui, Hallgeir; and Tanaka, Takemi, "Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer" (2020). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 117.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.